NCT06610045Completed
The Burden of Multiple Myeloma on Patients and Caregivers Quality of Life: a Canadian Real-World Study
Source: ClinicalTrials.gov · Last updated 13 Mar 2025
Brief summary (registry, in English)
The purpose of this observational study is to estimate the burden of multiple myeloma on patients and caregivers in terms of QoL. Additionally, this study will assess the correlation between QoL, obtained from commonly used and validated questionnaires, and the perceptions of both patients and caregivers respectively., obtain from a 10-point scale and a comment box.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 400 (actual)
- First submitted
- 12 Sept 2024
- Start date
- 15 Oct 2024
- Primary completion date
- 24 Feb 2025
- Lead sponsor
- PeriPharm
- Diseases
- Multiple myeloma
- NCT number
- NCT06610045
What you commit to
- Study type: Observational
- Participants enrolled: 400
- From 15 Oct 2024 to the primary completion date, 24 Feb 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- No exclusion criteria
Who the study is looking for
- 18 years of age or older;
- Part of the Myeloma Canada database;
- Identified as a patient with MM or
- Identified as a current caregiver of a patient with MM at the time of participation.
- Ability to read and understand English or French;
- Signature of informed consent form (ICF).
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| PROxy Network, an initiative of PeriPharm inc. Coordinator of this site? Confirm its status | Montreal | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.